Amarin Corporation plc
AMRNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jan 6, 2023 | Jefferies | $3.00(+138%) | $1.26 | Benzinga | |
| May 24, 2022 | Goldman Sachs | $1.50(+6%) | $1.41 | Benzinga | |
| May 5, 2022 | Northland Securities | Carl Byrnes | $2.00(+28%) | $1.56 | TipRanks Contributor |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Goldman Sachs | maintain | Sell | Jun 25, 2025 |
| Goldman Sachs | maintain | Sell | Apr 17, 2025 |
| Jefferies | downgrade | Buy →Hold | Oct 25, 2023 |
| Goldman Sachs | maintain | Sell | Jul 20, 2023 |
| Northland Capital Markets | maintain | Market Perform | Jul 19, 2023 |
| Jefferies | upgrade | Hold →Buy | Jan 6, 2023 |
| SVB Leerink | maintain | Market Perform | Oct 19, 2022 |
| Goldman Sachs | maintain | Sell | May 24, 2022 |
| JP Morgan | downgrade | Neutral →Underweight | May 6, 2022 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 5, 2022 |
| SVB Leerink | downgrade | Outperform →Market Perform | May 5, 2022 |
| SVB Leerink | maintain | Outperform | Feb 16, 2022 |
| SVB Leerink | maintain | Outperform | Jan 31, 2022 |
| Goldman Sachs | downgrade | Neutral →Sell | May 12, 2021 |
| SVB Leerink | maintain | Outperform | Feb 1, 2021 |
| SVB Leerink | maintain | Outperform | Sep 28, 2020 |
| Aegis Capital | maintain | Buy | May 4, 2020 |
| SVB Leerink | maintain | Outperform | May 4, 2020 |
| Citigroup | maintain | Buy | Apr 1, 2020 |
| Goldman Sachs | downgrade | Buy →Neutral | Mar 31, 2020 |
| Stifel | maintain | Hold | Mar 31, 2020 |
| Oppenheimer | upgrade | Underperform →Perform | Mar 31, 2020 |
| Jefferies | downgrade | Buy →Hold | Mar 31, 2020 |
| Goldman Sachs | upgrade | Neutral →Buy | Mar 13, 2020 |
| Oppenheimer | maintain | Underperform | Feb 26, 2020 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $-0.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $0.01 | $-0.10 | $39.5M | $43.8M |
| Jul 29, 2026 | $-0.02 | $-0.01 | $42.2M | $44.5M |
| Apr 29, 2026 | $-0.09 | $0.01 | $45.1M | $43.8M |
| Feb 25, 2026 | $0.01 | $0.07 | $49.2M | $50.6M |
| Oct 29, 2025 | $0.01 | $0.08 | $49.7M | $43.1M |
| Jul 30, 2025 | $-0.03 | $-0.66 | $72.7M | $53.8M |
| May 7, 2025 | $-0.04 | $-1.12 | $41.0M | $50.7M |
| Mar 12, 2025 | $-2.40 | $-0.40 | $62.3M | $36.0M |
News
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset continued U.S. pricing pressure for its VASCEPA cardiovascular therapy.
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026.
Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership. Institutional and Insider Ownership 22.3% of Amarin shares are
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.